6 Recommendations for further research

6 Recommendations for further research

6.1 The Committee considered that the following research would be of value:

  • Studies investigating the effectiveness of rituximab plus fludarabine and cyclophosphamide in people with relapsed and refractory chronic lymphocytic leukaemia that has previously been treated with rituximab.

  • Studies investigating the effectiveness of rituximab plus chemotherapy other than fludarabine and cyclophosphamide in people with relapsed and refractory chronic lymphocytic leukaemia.

  • Studies investigating the health-related quality of life of people with chronic lymphocytic leukaemia that include data collected using a generic preference-based measure.

  • National Institute for Health and Care Excellence (NICE)